Advertisement

Obg Management Logo Home
   
   
Free CME
Classifieds
Register/Login
Home Page Current Issue Past Issues Supplements Podcasts Information for Authors
                                    
   
About Us
Subscribe Renew
Reprints Permissions
Advertising Information
Links and Resources
Classifieds

Advertisement

August 2004 · Vol. 16, No. 8

Nausea and vomiting of pregnancy:
Q&A with T. Murphy Goodwin

An expert tells why this common condition is undertreated, and what can help, including how to formulate the effective drug formerly marketed as Bendectin.


JANELLE  YATES,  SENIOR ASSOCIATE EDITOR

KEY POINTS

  • About 35% of gravidas have nausea and vomiting severe enough to disrupt their daily routine. As many as 50% of women with severe NVP are not offered antiemetic therapy, studies show.

  • At any level of severity, nausea and vomiting cause psychosocial morbidity.

  • Multivitamin use at the time of conception reduces the severity of nausea and vomiting.

  • When drug therapy is necessary, start with 10 to 25 mg pyridoxine (vitamin B6) 3 or 4 times daily.

  • If nausea and vomiting continue, add 12.5 mg doxylamine (by halving the over-the-counter sleep aid Unisom) to each dose of pyridoxine. The pyridoxine-doxylamine combination is the same formulation as the highly effective drug Bendectin, which is no longer available in the US.

T. Murphy Goodwin, MD, a contributor to the new American College of Obstetricians and Gynecologists practice bulletin on nausea and vomiting of pregnancy (NVP),1 tells why it is important to ask every patient about nausea and vomiting, when to intervene, and what the best treatments are—including a substitute compound for the no-longer-available drug Bendectin.

Dr. Goodwin is professor of obstetrics and gynecology at the Keck School of Medicine, University of Southern California, Los Angeles.

Sign in now to read more...

Back to top


Advertisement



Advertisement1


XMLRSS callout
 

Advertisement